CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China : vimarsana.com

SUZHOU, China, Nov. 1, 2023 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research,

Related Keywords

China , United Kingdom , Shenyang , Liaoning , Lou Jing , Fujian , Suzhou , Jiangsu , Thailand , United States , British , American , Jason Yang , National Engineering Research Center , Sbio Inc , American Society Of Clinical Oncology , European Society For Medical Oncology , World Health Organization , Cstone Pharmaceuticals , Shenyang Sunshine Pharmaceutical Co Ltd , International Agency For Research On Cancer , British Journal , Medical Oncology , Annual Conference , Clinical Oncology , Orphan Drug Designation , Global Cancer Incidence , International Agency , Antibody Medicine , Cherish Life , Nat Rev Clin , Nat Rev Dis , Circulating Tumor Cells , Their Implications , Therapeutic Monitoring , Thailand Business ,